Michelle Crawley
President
Thank you for your interest in Xcision. We manufacturer GammaPod™, the world's first stereotactic radiotherapy system optimized for treating early-stage breast cancer.
The system is designed to deliver stereotactic body radiotherapy (SBRT) to reduce the length of treatment to between 1 to 5 sessions, spare healthy breast tissue and minimize dose to the heart and lungs. The system combines a dynamic treatment delivery system that conforms the dose to the target with sharp falloff, a first-of-its-kind breast immobilization system and automated prone positioning systems for quick and comfortable patient setup.
COLUMBIA, United States
Healthcare
Xcision Medical Systems, LLC is a medical technology company developing advanced stereotactic radiotherapy solutions with the potential to significantly improve the quality of cancer care as well as the lives of patients and their loved ones. The company’s technology is designed to extend the benefits of radiation oncology to more patients and enable precision noninvasive treatments that allow patients to return to living fuller lives more quickly with less discomfort after receiving a cancer diagnosis.
Xcision’s initial focus is on breast cancer, using stereotactic radiotherapy to deliver focused radiation to a partial volume of the breast in conjunction with breast conserving treatment. The company’s first product, GammaPod™, is a new stereotactic radiotherapy system optimized for the treatment of breast cancer. The delivery of higher doses in one or several large fractions differentiates stereotactic radiotherapy from conventional techniques. The system has been developed based on a patent licensed from the University of Maryland School of Medicine.
Xcision’s initial focus is on breast cancer, using stereotactic radiotherapy to deliver focused radiation to a partial volume of the breast in conjunction with breast conserving treatment. The company’s first product, GammaPod™, is a new stereotactic radiotherapy system optimized for the treatment of breast cancer. The delivery of higher doses in one or several large fractions differentiates stereotactic radiotherapy from conventional techniques. The system has been developed based on a patent licensed from the University of Maryland School of Medicine.
